Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Malignant Melanoma

Free Subscription Articles published in Melanoma Res Retrieve available abstracts of 201 articles: HTML format

Single Articles

February 2026
1. BROWNE FJ, Bollard SM, Ormond P, Kelleher F, et al
   Melanoma: a genetics guide for surgeons.
   Melanoma Res. 2026 Feb 16. doi: 10.1097/CMR.0000000000001082.
   PubMed     Abstract available
   
   
   
2. DEVOLDERE A, Bouche O, Barbe C, Didier K, et al
   Determinants of adjuvant treatment choice between immunotherapy (immune checkpoint inhibitor) and targeted therapy in resected stage III BRAF V600-mutated cutaneous melanoma: a multicenter observational study: MELADJ3.
   Melanoma Res. 2026 Feb 16. doi: 10.1097/CMR.0000000000001083.
   PubMed     Abstract available
   
   
   
3. KRISTJANSEN KA, Mensel C, Larsen MO, Dam-Dalgeir G, et al
   Safety of tranexamic acid in patients with stage III melanoma undergoing lymph node dissection: a retrospective cohort study.
   Melanoma Res. 2026 Feb 11. doi: 10.1097/CMR.0000000000001084.
   PubMed     Abstract available
   
   
   
4. POZUELO-RUIZ M, de Unamuno-Bustos B, Navarro-Blanco F, Palacios-Diaz RD, et al
   Survival and toxicity profile of elderly melanoma patients treated with immune checkpoint inhibitors: a retrospective study from a tertiary care center.
   Melanoma Res. 2026 Feb 4. doi: 10.1097/CMR.0000000000001076.
   PubMed     Abstract available
   
   
   
5. MULLINS KR, Guo JJ
   Trends of adverse event reports associated with BRAF and MEK inhibitors and combinations: a retrospective disproportionality analysis using the FDA adverse event reporting system database from 2012 to 2021.
   Melanoma Res. 2026;36:58-63.
   PubMed     Abstract available
   
   
   January 2026
6. STRATIGOS IA, Dessinioti C, Nikolaou V, Befon A, et al
   Divergent pathways of melanoma development: evidence from a Southern European cohort.
   Melanoma Res. 2026 Jan 29. doi: 10.1097/CMR.0000000000001075.
   PubMed     Abstract available
   
   
   
7. BILIK SM, Burke OM, Elman SA
   Chromosome 1p13.2 gene cluster upregulation in neuroblastoma RAS viral oncogene homolog pathogenic variant melanoma: a potential biomarker axis.
   Melanoma Res. 2026 Jan 29. doi: 10.1097/CMR.0000000000001080.
   PubMed     Abstract available
   
   
   
8. KISSINGER CR, Miller DJ, Li Z, Ashraf UM, et al
   Circulating tumor DNA accelerates diagnosis and treatment guidance for metastatic uveal melanoma with hepatic lesions not amenable to biopsy.
   Melanoma Res. 2026 Jan 29. doi: 10.1097/CMR.0000000000001077.
   PubMed     Abstract available
   
   
   
9. DUARTE-BATEMAN D, Escandon JM, Shen A, Chen Y, et al
   Treatment effect of neoadjuvant immunotherapy in melanoma correlates with tumor burden: meta-analysis of reported clinical trials.
   Melanoma Res. 2026 Jan 29. doi: 10.1097/CMR.0000000000001079.
   PubMed     Abstract available
   
   
   December 2025
10. MATTEI J, Ruitao L, Davies MA, Wong MK, et al
    Adjuvant therapy in mucosal melanoma: a single-center experience and review of the literature.
    Melanoma Res. 2025 Dec 4. doi: 10.1097/CMR.0000000000001073.
    PubMed     Abstract available
    
    
    
11. KOSTAKI M, Porfiriou G, Louros L, Manousaki M, et al
    Epidemiologic characteristics of de novo versus nevus-associated melanoma.
    Melanoma Res. 2025;35:418-423.
    PubMed     Abstract available
    
    
    November 2025
12. TIAN Z
    A deep learning-based radiomics model for noninvasive diagnosis of melanoma.
    Melanoma Res. 2025 Nov 14. doi: 10.1097/CMR.0000000000001071.
    PubMed     Abstract available
    
    
    
13. CAI M, Wang L, Yang W, Niu J, et al
    Breaking barriers: epithelial-mesenchymal transition role in melanoma invasion and resistance.
    Melanoma Res. 2025 Nov 13. doi: 10.1097/CMR.0000000000001068.
    PubMed     Abstract available
    
    
    
14. BOUILLENNE A, Quatresooz P, Collins P, Nikkels AF, et al
    Retro- and prospective histologic and immunohistochemical analysis of safety margins following complete excision of less than 1 mm melanomas.
    Melanoma Res. 2025 Nov 10. doi: 10.1097/CMR.0000000000001070.
    PubMed     Abstract available
    
    
    
15. SREERAM A, Postow MA, Moy AP, Ariyan CE, et al
    Thinking beyond immunotherapy: implementing a multimodal care plan to facilitate extended survival in stage IV melanoma.
    Melanoma Res. 2025 Nov 10. doi: 10.1097/CMR.0000000000001072.
    PubMed     Abstract available
    
    
    October 2025
16. COMANICI M, Robertus JL, Rice A, Nathan P, et al
    Surgical management of pulmonary metastases secondary to uveal melanoma: a case series.
    Melanoma Res. 2025 Oct 17. doi: 10.1097/CMR.0000000000001066.
    PubMed     Abstract available
    
    
    
17. SUBRAMANIAN K, Parameswaran S, Maradani BS, Khetan V, et al
    Chromosomal 6q loss as a prognostic biomarker in Indian uveal melanoma: an OncoScan FFPE Assay study.
    Melanoma Res. 2025 Oct 17. doi: 10.1097/CMR.0000000000001067.
    PubMed     Abstract available
    
    
    
18. DE GIORGI V, Fazzari F, Cecchi G, Perillo G, et al
    Multiple melanoma, ichthyosis, and juvenile cataracts in a patient with a germline mutation in CDKN2A: pure coincidence or related association?
    Melanoma Res. 2025;35:367-368.
    PubMed    
    
    
    
19. XUE GR, Clark M, Slaven JE, Que SKT, et al
    Rurality as a predictor of melanoma stage and treatment in Indiana: a retrospective cohort study.
    Melanoma Res. 2025;35:366-367.
    PubMed    
    
    
    September 2025
20. DAVIES L, Skepastianos V, Palazi C, Skepastianos G, et al
    Contralateral axillary sentinel lymph node in chest wall melanoma: first documented case and narrative review of the literature.
    Melanoma Res. 2025 Sep 26. doi: 10.1097/CMR.0000000000001065.
    PubMed     Abstract available
    
    
    
21. FUCINA S, Lerda L, Del Fabro A, Reato C, et al
    Late peritoneal carcinomatosis from cutaneous melanoma mimicking ovarian cancer.
    Melanoma Res. 2025 Sep 10. doi: 10.1097/CMR.0000000000001064.
    PubMed     Abstract available
    
    
    
22. CEREZUELA-FUENTES P, Aguado de la Rosa C, Crespo G, Berciano-Guerrero MA, et al
    Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study.
    Melanoma Res. 2025 Sep 3. doi: 10.1097/CMR.0000000000001062.
    PubMed     Abstract available
    
    
    August 2025
23. ZHU JJ, Sahoo A, Song JJ, Vangala VNP, et al
    A high range of intrinsic disorder values for tumor resident, T-cell receptor beta V-complementarity determining region 3-J amino acid sequence assemblies correlates with better melanoma outcomes.
    Melanoma Res. 2025 Aug 29. doi: 10.1097/CMR.0000000000001061.
    PubMed     Abstract available
    
    
    
24. ACAR FP, Acar C, Yuksel HC, Sahin G, et al
    Integrating neutrophils, lymphocytes and eosinophils: development and validation of the NLE Index in ICI-treated metastatic melanoma.
    Melanoma Res. 2025 Aug 29. doi: 10.1097/CMR.0000000000001060.
    PubMed     Abstract available
    
    
    
25. CHANG RC, Brunsgaard EK, Reid DC
    Treatment and survival disparities in acral lentiginous melanoma: a National Cancer Database multivariate analysis.
    Melanoma Res. 2025 Aug 5. doi: 10.1097/CMR.0000000000001059.
    PubMed     Abstract available
    
    
    
26. VAN AMMERS M, Tracey T, Yazdabadi A, Ciconte A, et al
    A survey of skin check rates in an outpatient oncology melanoma clinic.
    Melanoma Res. 2025;35:290-291.
    PubMed    
    
    
    July 2025
27. KIM HY, Choi YJ, Jeong KM, Jeong HJ, et al
    Compound 48/80 suppresses melanoma growth by inducing apoptosis and enhancing immune response.
    Melanoma Res. 2025 Jul 22. doi: 10.1097/CMR.0000000000001057.
    PubMed     Abstract available
    
    
    
28. DI RAIMONDO C, Fico A, Cicala M, Caposiena Caro RD, et al
    Peripheral blood inflammation indexes correlate with advanced stages in cutaneous melanoma: a single-center retrospective study.
    Melanoma Res. 2025 Jul 17. doi: 10.1097/CMR.0000000000001056.
    PubMed     Abstract available
    
    
    
29. ZHANG LP, Zhang ZG, Guan J, Li LQ, et al
    Thrombospondin 2 drives liver metastasis in skin cutaneous melanoma via regulation of angiogenesis and extracellular matrix remodeling.
    Melanoma Res. 2025 Jul 16. doi: 10.1097/CMR.0000000000001055.
    PubMed     Abstract available
    
    
    
30. GIRONI LC, Zottarelli F, Esposto E, Cammarata E, et al
    Dermatologic surveillance in healthy carriers of CDKN2A and p.E318K MITF germline variants from melanoma-prone families: a 14 years hospital-based experience.
    Melanoma Res. 2025 Jul 3. doi: 10.1097/CMR.0000000000001054.
    PubMed     Abstract available
    
    
    
31. CHAI Y, Zhao J, Wang X, Li B, et al
    Upregulation of SFTPC gene expression is associated with disease progression and worse survival outcomes in human skin melanomas.
    Melanoma Res. 2025 Jul 1. doi: 10.1097/CMR.0000000000001051.
    PubMed     Abstract available
    
    
    June 2025
32. KRISTJANSEN KA, Birk-Sorensen L, Bonnelykke-Behrndtz ML
    Perioperative neutrophil-to-lymphocyte ratio in patients with melanoma: a pilot study assessing surgical stress after sentinel lymph node biopsy.
    Melanoma Res. 2025 Jun 26. doi: 10.1097/CMR.0000000000001052.
    PubMed     Abstract available
    
    
    
33. PANDIT-TASKAR N, Mauguen A, Frosina D, Jungbluth A, et al
    Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study.
    Melanoma Res. 2025 Jun 25. doi: 10.1097/CMR.0000000000001050.
    PubMed     Abstract available
    
    
    
34. KREUZ M, Moraes FCA, Lobo AOM, Skov RPH, et al
    Updated meta-analysis on the risk of melanoma associated with phosphodiesterase type 5 inhibitors.
    Melanoma Res. 2025 Jun 6. doi: 10.1097/CMR.0000000000001049.
    PubMed     Abstract available
    
    
    
35. BERKAOUI I, Zourdani L, Janela-Lapert R
    Postimmunotherapy antiglial fibrillary acidic protein encephalomyelitis after adjuvant pembrolizumab for melanoma.
    Melanoma Res. 2025 Jun 4. doi: 10.1097/CMR.0000000000001048.
    PubMed     Abstract available
    
    
    
36. CHAVERON M, Toulemonde E, Desmedt E, Boileau M, et al
    Resolution of diffuse cuticular melanosis under immunotherapy in a patient with metastatic melanoma.
    Melanoma Res. 2025;35:213-215.
    PubMed    
    
    
    May 2025
37. BERTOLLI E, Micheletti SB, de Camargo VP, da Silva TV, et al
    Nomograms versus artificial intelligence platforms: which one can better predict sentinel node positivity in melanoma patients?
    Melanoma Res. 2025 May 27. doi: 10.1097/CMR.0000000000001047.
    PubMed     Abstract available
    
    
    
38. KREUZ M, de Souza Wagner PH, Tanimoto LE, da Rosa VA, et al
    Melanoma and pregnant women: a systematic review and meta-analysis.
    Melanoma Res. 2025 May 27. doi: 10.1097/CMR.0000000000001043.
    PubMed     Abstract available
    
    
    
39. BLOHOWIAK RF, Welch NW, Rigden BW, Varman RM, et al
    Evaluation of surgical modalities for stage 0 to stage II acral lentiginous melanoma: a National Cancer Database study.
    Melanoma Res. 2025 May 27. doi: 10.1097/CMR.0000000000001046.
    PubMed     Abstract available
    
    
    
40. MYNAM RS, Menon N, Birbrair A, Ma VT, et al
    Successful use of nivolumab and relatlimab as salvage therapy for metastatic uveal melanoma.
    Melanoma Res. 2025 May 27. doi: 10.1097/CMR.0000000000001045.
    PubMed     Abstract available
    
    
    
41. VAN RYAN V, Zahrieh D, Strand C, Churchill RA, et al
    Impact of systemic imaging surveillance on survival from metastatic uveal melanoma.
    Melanoma Res. 2025 May 19. doi: 10.1097/CMR.0000000000001042.
    PubMed     Abstract available
    
    
    
42. PALACIOS-DIAZ RD, de Unamuno-Bustos B, Carratala-Garcia A, Perez-Simo G, et al
    Circulating tumor DNA predicts tumor progression and poor survival in patients with stage III melanoma.
    Melanoma Res. 2025 May 19. doi: 10.1097/CMR.0000000000001041.
    PubMed     Abstract available
    
    
    April 2025
43. JOERGER M, Diem S, Wyss N, Koster KL, et al
    Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA).
    Melanoma Res. 2025 Apr 17. doi: 10.1097/CMR.0000000000001040.
    PubMed     Abstract available
    
    
    
44. ACAR C, Yuksel HC, Sahin G, Acar FP, et al
    C-reactive protein kinetics as prognostic biomarkers in advanced melanoma treated with immune checkpoint inhibitors.
    Melanoma Res. 2025 Apr 8. doi: 10.1097/CMR.0000000000001039.
    PubMed     Abstract available
    
    
    
45. MATTEI J, Trindade EN, Chedid MF
    Mucosal melanoma: from molecular landscape to current treatment strategies: Erratum.
    Melanoma Res. 2025;35:153.
    PubMed    
    
    
    
46. MARSIGLIO J, McPherson J, Wahl M, Hu-Lieskovan S, et al
    Pembrolizumab-induced acquired lipodystrophy: a case report and review of the literature.
    Melanoma Res. 2025;35:109-114.
    PubMed     Abstract available
    
    
    
47. DAVIDSON SJ, Teoh DGK, Dudek AZ, Vogel RI, et al
    Immunotherapy for treatment of female genital tract melanoma: National Cancer Database analysis.
    Melanoma Res. 2025 Apr 1. doi: 10.1097/CMR.0000000000001036.
    PubMed     Abstract available
    
    
    
48. PEDERSEN S, Borch TH, Svane IM, Donia M, et al
    Steroid-refractory severe immune-related mucositis following adjuvant anti-PD-1 therapy for resectable melanoma: a case report.
    Melanoma Res. 2025 Apr 1. doi: 10.1097/CMR.0000000000001037.
    PubMed     Abstract available
    
    
    March 2025
49. BUJA A, Rugge M, Formaro CM, Grotto G, et al
    A real-world direct cost associated with a 4-year postdiagnosis follow-up in a population-based cohort of patients with melanoma by clinical-pathological characteristics.
    Melanoma Res. 2025 Mar 28. doi: 10.1097/CMR.0000000000001033.
    PubMed     Abstract available
    
    
    
50. HINNEN C, Tijssens F, von Haeseler E, van de Berg S, et al
    Do cortisol and psychological distress levels impact the effectiveness of immunotherapy in patients with metastasized melanoma? A pilot study.
    Melanoma Res. 2025 Mar 25. doi: 10.1097/CMR.0000000000001035.
    PubMed     Abstract available
    
    
    
51. GUYON M, Faure M, Pernot M, Pham-Ledard A, et al
    Management of cardiac metastases of melanoma in the era of immunotherapy: a case series.
    Melanoma Res. 2025 Mar 25. doi: 10.1097/CMR.0000000000001032.
    PubMed     Abstract available
    
    
    
52. TAS F, Ahishali E, Taskin OC
    Nivolumab-induced immune-mediated acute gastritis in a melanoma patient.
    Melanoma Res. 2025 Mar 21. doi: 10.1097/CMR.0000000000001034.
    PubMed     Abstract available
    
    
    February 2025
53. JANSSEN S, Moufarrej A, Springer R, Haberle L, et al
    Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors.
    Melanoma Res. 2025 Feb 27. doi: 10.1097/CMR.0000000000001028.
    PubMed     Abstract available
    
    
    
54. GUGLIELMO A, De Benedittis A, Buligan C, Zelin E, et al
    Multiple primary melanomas in Udine, northeastern Italy: a focus on epidemiology and new risk factors.
    Melanoma Res. 2025 Feb 27. doi: 10.1097/CMR.0000000000001029.
    PubMed     Abstract available
    
    
    
55. BEITNER A, Abu-Abeid A, Dayan D, Gat A, et al
    Patterns of expression and prognostic implication of glycoprotein nonmetastatic protein B (GPNMB) expression in sentinel lymph nodes of melanoma patients.
    Melanoma Res. 2025 Feb 14. doi: 10.1097/CMR.0000000000001019.
    PubMed     Abstract available
    
    
    
56. AMRANE K, Le Noac'h P, Hemon P, Abgral R, et al
    MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors.
    Melanoma Res. 2025 Feb 12. doi: 10.1097/CMR.0000000000001022.
    PubMed     Abstract available
    
    
    
57. GONZALEZ-BARRALLO I, Castellon Rubio VE, Medina J, Espana Fernandez S, et al
    Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study.
    Melanoma Res. 2025 Feb 7. doi: 10.1097/CMR.0000000000001020.
    PubMed     Abstract available
    
    
    
58. KERKOUR T, Meijers RWJ, Hollestein LM, Jansen AML, et al
    Genetic concordance in melanoma: insights from primary tumors and their matched distant metastases.
    Melanoma Res. 2025 Feb 6. doi: 10.1097/CMR.0000000000001024.
    PubMed     Abstract available
    
    
    
59. TAS F, Erturk K
    Brain metastases during follow-up of patients with resected cutaneous melanoma.
    Melanoma Res. 2025 Feb 4. doi: 10.1097/CMR.0000000000001026.
    PubMed     Abstract available
    
    
    
60. BHATT KA, Vaynrub AJ, Cham J, Iyer SG, et al
    Diagnosis and management of concurrent metastatic melanoma and chronic myelomonocytic leukemia.
    Melanoma Res. 2025 Feb 4. doi: 10.1097/CMR.0000000000001025.
    PubMed     Abstract available
    
    
    
61. SHEN YC, Huang YL, Kang YN, Chiu WK, et al
    Effectiveness and safety of talimogene laherparepvec and granulocyte-macrophage colony-stimulating factor for metastatic melanoma: a systematic review and network meta-analysis of randomized controlled trials.
    Melanoma Res. 2025;35:60-66.
    PubMed     Abstract available
    
    
    January 2025
62. ANGELL CD, Sun SH, Lapurga G, Benner B, et al
    A comparison of myeloid-derived suppressor cell populations in patients with ulcerated vs non-ulcerated melanoma receiving immune checkpoint blockade.
    Melanoma Res. 2025 Jan 29. doi: 10.1097/CMR.0000000000001023.
    PubMed     Abstract available
    
    
    
63. CHEN L, Cai B, Ni X, Lin Q, et al
    Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety.
    Melanoma Res. 2025 Jan 28. doi: 10.1097/CMR.0000000000001021.
    PubMed     Abstract available
    
    
    
64. BASSI V, Apuzzi V, Vanella V, Facchini BA, et al
    SIAD onset in a patient affected by metastatic melanoma treated with immune checkpoint inhibitors: the role of nivolumab treatment.
    Melanoma Res. 2025 Jan 7. doi: 10.1097/CMR.0000000000001017.
    PubMed    
    
    
    
65. POZUELO-RUIZ M, de Unamuno-Bustos B, Palacios-Diaz RD, Blanes-Martinez MDM, et al
    Vitiligo-like hypopigmentation secondary to adjuvant checkpoint inhibitor therapy in patients with resectable stage III melanoma: a cohort from two tertiary hospitals.
    Melanoma Res. 2025 Jan 7. doi: 10.1097/CMR.0000000000001018.
    PubMed     Abstract available
    
    
    December 2024
66. AL-NAESAN I, Krepper D, Sparano F, Sztankay M, et al
    Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results.
    Melanoma Res. 2024 Dec 11. doi: 10.1097/CMR.0000000000001014.
    PubMed     Abstract available
    
    
    
67. LEIBOVIT-REIBEN Z, Godfrey H, Jedlowski P, Thiede R, et al
    Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System.
    Melanoma Res. 2024 Dec 6. doi: 10.1097/CMR.0000000000001015.
    PubMed     Abstract available
    
    
    
68. ESMAELI B, Ogden T, Nichols M, Lu T, et al
    Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma.
    Melanoma Res. 2024 Dec 6. doi: 10.1097/CMR.0000000000001016.
    PubMed     Abstract available
    
    
    
69. WITTEVEEN SJ, Klop WMC, van Dijk-de Haan MC, Karssemakers LHE, et al
    Melanoma in the head and neck region: the value of preoperative imaging in melanoma stage I-II.
    Melanoma Res. 2024 Dec 3. doi: 10.1097/CMR.0000000000001013.
    PubMed     Abstract available
    
    
    
70. HORISAKI K, Yoshikawa S, Omata W, Tsutsumida A, et al
    Clinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort study.
    Melanoma Res. 2024 Dec 3. doi: 10.1097/CMR.0000000000001012.
    PubMed     Abstract available
    
    
    
71. BURSHTEIN J, Shah M, Zakria D, Rigel D, et al
    The association between dermatologist density and melanoma prognosis using melanoma mortality-incidence ratio.
    Melanoma Res. 2024;34:550-552.
    PubMed    
    
    
    
72. ARJUNAN A, Wardrop M, Malek MM, Davit AJ 3rd, et al
    Treatment outcomes following partial shave biopsy of atypical and malignant melanocytic tumors in pediatric patients.
    Melanoma Res. 2024;34:544-548.
    PubMed     Abstract available
    
    
    November 2024
73. NIU L, Liu S, Shen J, Chang J, et al
    ATF3 regulates CDC42 transcription and influences cytoskeleton remodeling, thus inhibiting the proliferation, migration and invasion of malignant skin melanoma cells.
    Melanoma Res. 2024 Nov 26. doi: 10.1097/CMR.0000000000001011.
    PubMed     Abstract available
    
    
    
74. MACAIRE C, Lefevre W, Dalac S, Montaudie H, et al
    Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort.
    Melanoma Res. 2024 Nov 11. doi: 10.1097/CMR.0000000000000973.
    PubMed     Abstract available
    
    
    October 2024
75. ZHENG L, Susanto AK, Soyer HP, Janda M, et al
    Psychosocial wellbeing in people with melanoma in-situ: a systematic review.
    Melanoma Res. 2024 Oct 10. doi: 10.1097/CMR.0000000000001007.
    PubMed     Abstract available
    
    
    
76. KREUZ M, de Moraes FCA, Sano VKT, Westphal Filho FL, et al
    Association of baseline neutrophil-to-lymphocyte ratio and prognosis in melanoma patients treated with PD-1/PD-L1 blockade: a systematic review and meta-analysis.
    Melanoma Res. 2024 Oct 8. doi: 10.1097/CMR.0000000000001006.
    PubMed     Abstract available
    
    
    
77. CAMPILLO P, Kesler A, Ramirez CA, Ramirez CJ, et al
    International incidence of melanoma in heart transplant recipients: a meta-analysis.
    Melanoma Res. 2024 Oct 7. doi: 10.1097/CMR.0000000000001008.
    PubMed     Abstract available
    
    
    
78. PAOLINO G, Podo Brunetti A, De Rosa C, Cantisani C, et al
    Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma.
    Melanoma Res. 2024 Oct 4. doi: 10.1097/CMR.0000000000001003.
    PubMed     Abstract available
    
    
    
79. 
    Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma: Erratum.
    Melanoma Res. 2024;34:473.
    PubMed    
    
    
    
80. MATTIUZZI C, Lippi G
    The death rate for melanoma remained unchanged in the USA during the coronavirus disease 2019 pandemic.
    Melanoma Res. 2024;34:472.
    PubMed    
    
    
    September 2024
81. NACCHIERO E, Giotta M, Robusto F, Metta ME, et al
    The role of wide local excision of a primary lesion in cutaneous malignant melanoma: a retrospective analysis of its usefulness in local and general control of disease.
    Melanoma Res. 2024 Sep 25. doi: 10.1097/CMR.0000000000000999.
    PubMed     Abstract available
    
    
    
82. STAWIARZ M, Hoang MP, Kowalik A
    High-resolution RNA-sequencing reveals TRIM33::CSDE1 gene fusion in metastasizing vulvar melanoma.
    Melanoma Res. 2024 Sep 18. doi: 10.1097/CMR.0000000000001005.
    PubMed     Abstract available
    
    
    
83. MCKECHNIE T, Talwar G, Grewal S, Wang A, et al
    The impact of statins on melanoma survival: a systematic review and meta-analysis.
    Melanoma Res. 2024 Sep 12. doi: 10.1097/CMR.0000000000001001.
    PubMed     Abstract available
    
    
    August 2024
84. STOFF R, Markovic SN, McWilliams RR, Kottschade LA, et al
    Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting.
    Melanoma Res. 2024 Aug 30. doi: 10.1097/CMR.0000000000000997.
    PubMed     Abstract available
    
    
    
85. KIM I, Oh J, Yoon S, Han MY, et al
    Pediatric melanoma incidence and survival: a fifteen-year nationwide retrospective cohort study in Korea (2004-2019).
    Melanoma Res. 2024 Aug 30. doi: 10.1097/CMR.0000000000001000.
    PubMed     Abstract available
    
    
    
86. ZWEEDIJK BE, Schurink AW, van Dalen T, van Ginhoven TM, et al
    Transcutaneous sentinel lymph node detection in skin melanoma with near-infrared fluorescence imaging using indocyanine green.
    Melanoma Res. 2024 Aug 2. doi: 10.1097/CMR.0000000000000994.
    PubMed     Abstract available
    
    
    
87. WANG S, Zhou H, Ma Y, Jin S, et al
    A retrospective study of clinicopathological and prognostic characteristics in 177 Chinese patients with acral melanoma: heterogeneity based on tumor site.
    Melanoma Res. 2024;34:390-392.
    PubMed    
    
    
    
88. KIBBIE JJ, Zita SM, Dellavalle RP, Dunnick CA, et al
    The number needed to biopsy for cutaneous melanoma in academic dermatology clinics.
    Melanoma Res. 2024;34:350-354.
    PubMed     Abstract available
    
    
    
89. ORLANDI E, Ceccuzzi L, Belpinati F, Rodolfo M, et al
    Sex-dependent interaction of PTGS2 with miR-146a as risk factor for melanoma and the impact of sex hormones in gene expression in skin cells.
    Melanoma Res. 2024;34:296-306.
    PubMed     Abstract available
    
    
    
90. OZLUK AA, Gunenc D, Yildirim SS, Karaca B, et al
    Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature.
    Melanoma Res. 2024;34:335-342.
    PubMed     Abstract available
    
    
    July 2024
91. ZHANG S, Liu Z, Zhu D
    Development and validation of prognostic nomogram in pediatric melanoma: a population-based study.
    Melanoma Res. 2024 Jul 31. doi: 10.1097/CMR.0000000000000993.
    PubMed     Abstract available
    
    
    
92. ELMES JB, Davis JM, Musselwhite LW, Chiad Z, et al
    Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis.
    Melanoma Res. 2024 Jul 22. doi: 10.1097/CMR.0000000000000992.
    PubMed     Abstract available
    
    
    
93. TSIMPIDAKIS A, Koumprentziotis IA, Mastoraki E, Plaka M, et al
    Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight.
    Melanoma Res. 2024 Jul 22. doi: 10.1097/CMR.0000000000000991.
    PubMed     Abstract available
    
    
    
94. CHANDRASEKARAN S, Ling YL, Tang J
    Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF-mutated melanoma patients in the United States.
    Melanoma Res. 2024 Jul 16. doi: 10.1097/CMR.0000000000000990.
    PubMed     Abstract available
    
    
    
95. FOKKEN C, Silbern I, Shomroni O, Pan KT, et al
    Interfering with aggregated alpha-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins.
    Melanoma Res. 2024 Jul 2. doi: 10.1097/CMR.0000000000000982.
    PubMed     Abstract available
    
    
    June 2024
96. LOCHRIN SE, Cugliari MK, Yeh R, Shoushtari AN, et al
    Efficacy of axitinib in a US cohort of patients with programmed cell death protein 1-resistant mucosal melanoma.
    Melanoma Res. 2024 Jun 28. doi: 10.1097/CMR.0000000000000988.
    PubMed     Abstract available
    
    
    
97. DE GIORGI V, Cecchi G, Perillo G, Zuccaro B, et al
    Synchronous double primary vulvar melanoma: a not so rare possibility. A clinical and dermoscopic case study.
    Melanoma Res. 2024 Jun 24. doi: 10.1097/CMR.0000000000000989.
    PubMed     Abstract available
    
    
    
98. ASHER N, Bar-Hai N, Ben-Betzalel G, Stoff R, et al
    Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy.
    Melanoma Res. 2024 Jun 24. doi: 10.1097/CMR.0000000000000985.
    PubMed     Abstract available
    
    
    
99. SHEMER M, Shimonovitz M, Furer R, Abu-Abeid A, et al
    Long-term outcomes and patterns of recurrence in patients with thin melanoma and a negative sentinel lymph node biopsy: a single-center experience.
    Melanoma Res. 2024 Jun 14. doi: 10.1097/CMR.0000000000000986.
    PubMed     Abstract available
    
    
    
100. BUSTAMANTE P, Coblentz J, Mastromonaco C, Youhnovska E, et al
     Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model.
     Melanoma Res. 2024 Jun 7. doi: 10.1097/CMR.0000000000000964.
     PubMed     Abstract available
     
     
     
101. LIU H, Jiang H, Shan Q
     Reflectance confocal microscopy versus dermoscopy for the diagnosis of cutaneous melanoma: a head-to-head comparative meta-analysis.
     Melanoma Res. 2024 Jun 7. doi: 10.1097/CMR.0000000000000980.
     PubMed     Abstract available
     
     
     
102. LUO P, Guo R, Gao D, Zhang Q, et al
     Causal relationship between sex hormones and cutaneous melanoma: a two-sample Mendelian randomized study.
     Melanoma Res. 2024 Jun 5. doi: 10.1097/CMR.0000000000000983.
     PubMed     Abstract available
     
     
     
103. DINI F, Susini P, Zuccaro B, Nisi G, et al
     Head and neck melanoma: the eyelid region has a better prognosis and easier management: a retrospective survey and systematic review.
     Melanoma Res. 2024 Jun 3. doi: 10.1097/CMR.0000000000000984.
     PubMed     Abstract available
     
     
     
104. SHAH H, Parisi R, Everdell E, Feustel P, et al
     The effect of COVID-19 on early melanoma detection.
     Melanoma Res. 2024;34:283-284.
     PubMed    
     
     
     May 2024
105. SAMLOWSKI W, Silver MA, Hohlbauch A, Zhang S, et al
     Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma.
     Melanoma Res. 2024 May 27. doi: 10.1097/CMR.0000000000000962.
     PubMed     Abstract available
     
     
     
106. VANDER MIJNSBRUGGE AS, Cerckel J, Dirven I, Tijtgat J, et al
     Regorafenib in patients with pretreated advanced melanoma: a single-center case series.
     Melanoma Res. 2024 May 27. doi: 10.1097/CMR.0000000000000977.
     PubMed     Abstract available
     
     
     
107. INDINI A, Gueli R, Cerati M, Rijavec E, et al
     Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma.
     Melanoma Res. 2024 May 20. doi: 10.1097/CMR.0000000000000981.
     PubMed     Abstract available
     
     
     
108. ALBERTINI MR, Zuleger CL, Ranheim EA, Shiyanbola O, et al
     Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma.
     Melanoma Res. 2024 May 20. doi: 10.1097/CMR.0000000000000975.
     PubMed     Abstract available
     
     
     April 2024
109. GAO Y, Wang Y, Luo Y, Zhang Y, et al
     Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors.
     Melanoma Res. 2024 Apr 22. doi: 10.1097/CMR.0000000000000972.
     PubMed     Abstract available
     
     
     
110. WU LW, Tao JJ, McDonnell D, Izar B, et al
     Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition.
     Melanoma Res. 2024 Apr 18. doi: 10.1097/CMR.0000000000000974.
     PubMed     Abstract available
     
     
     
111. SUWAJANAKORN D, Lane AM, Go AK, Hartley CD, et al
     Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma.
     Melanoma Res. 2024 Apr 5. doi: 10.1097/CMR.0000000000000971.
     PubMed     Abstract available
     
     
     
112. HENNEMANN A, Puzenat E, Decreuse M, Vuillier F, et al
     Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.
     Melanoma Res. 2024 Apr 5. doi: 10.1097/CMR.0000000000000820.
     PubMed     Abstract available
     
     
     
113. MAIONE V, Perantoni M, Bettolini L, Bighetti S, et al
     Influence of regression, its extent and tumor-infiltrating lymphocytes on sentinel node status, relapse, and survival in a 10-year retrospective study of melanoma patients.
     Melanoma Res. 2024 Apr 2. doi: 10.1097/CMR.0000000000000970.
     PubMed     Abstract available
     
     
     March 2024
114. KODALI N, Bhattaru A, Blanchard I, Sharma Y, et al
     Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.
     Melanoma Res. 2024 Mar 29. doi: 10.1097/CMR.0000000000000968.
     PubMed     Abstract available
     
     
     
115. FABRE M, Lamoureux A, Meunier L, Samaran Q, et al
     Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
     Melanoma Res. 2024 Mar 28. doi: 10.1097/CMR.0000000000000963.
     PubMed     Abstract available
     
     
     
116. NEKKANTI SS, Nusrath S, Jarang R, Rayani BK, et al
     Feasibility and efficacy of indocyanine green in monitoring systemic drug leakage during isolated limb perfusion for recurrent melanoma of extremity.
     Melanoma Res. 2024 Mar 15. doi: 10.1097/CMR.0000000000000967.
     PubMed     Abstract available
     
     
     
117. LEROY M, Desmedt E, Deramoudt L, Vasseur M, et al
     Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma.
     Melanoma Res. 2024 Mar 15. doi: 10.1097/CMR.0000000000000965.
     PubMed     Abstract available
     
     
     
118. WANG P, Liu T, Zhang Q, Luo P, et al
     Genetic causal relationship between gut microbiota and cutaneous melanoma: a two-sample Mendelian randomization study.
     Melanoma Res. 2024 Mar 11. doi: 10.1097/CMR.0000000000000960.
     PubMed     Abstract available
     
     
     
119. NG CA, Luckett T, Mulhern B, Kee D, et al
     What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life.
     Melanoma Res. 2024 Mar 5. doi: 10.1097/CMR.0000000000000961.
     PubMed     Abstract available
     
     
     February 2024
120. DE PINTO G, Mignozzi S, La Vecchia C, Levi F, et al
     Global trends in cutaneous malignant melanoma incidence and mortality.
     Melanoma Res. 2024 Feb 21. doi: 10.1097/CMR.0000000000000959.
     PubMed     Abstract available
     
     
     
121. TEIXEIRA RJ, de Souza VG, Sorroche BP, Paes VG, et al
     Immunohistochemistry assessment of tissue neutrophil-to-lymphocyte ratio (tNLR) predicts outcomes in melanoma patients treated with anti-programmed cell death 1 therapy.
     Melanoma Res. 2024 Feb 16. doi: 10.1097/CMR.0000000000000958.
     PubMed     Abstract available
     
     
     
122. ZHANG W, Wang S
     Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma.
     Melanoma Res. 2024 Feb 16. doi: 10.1097/CMR.0000000000000957.
     PubMed     Abstract available
     
     
     
123. DE SMEDT J, Aura C, Van Kelst S, Janssen L, et al
     Clinical and genetic determinants of vitamin D receptor expression in cutaneous melanoma patients.
     Melanoma Res. 2024 Feb 13. doi: 10.1097/CMR.0000000000000929.
     PubMed     Abstract available
     
     
     
124. DELZENNE G, Boileau M, Jamme P, Farchi O, et al
     Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice.
     Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000955.
     PubMed     Abstract available
     
     
     
125. ERCAN A, Yalcin CE
     Neonatal cutaneous melanoma with cutaneous metastasis: a case report and review of literature.
     Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000956.
     PubMed     Abstract available
     
     
     
126. DIAZ MJ, Quach J, Song J, Milanovic S, et al
     Hypoxic transcriptomes predict survival and tumor-infiltrating immune cell composition in cutaneous melanoma.
     Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000938.
     PubMed     Abstract available
     
     
     
127. GEIGER CE, Mrabet-Dahbi S, Berger I
     The BRAF and NRAS status among distinct metastases of malignant melanoma differ significantly independent of tissue origin and temporal occurrence. Possible effect on clinical relevance?
     Melanoma Res. 2024;34:85-87.
     PubMed    
     
     
     
128. ROSTER K, Thang C, Islam S, Lipner SR, et al
     Underreporting of acral lentiginous melanoma in studies informing American Joint Committee on Cancer Staging System Guidelines: a review of 150 cited studies.
     Melanoma Res. 2024;34:84-88.
     PubMed    
     
     
     
129. DUARTE R, Trigo F, Luz I, Santos P, et al
     Small-vessel vasculitis leading to severe acute kidney injury after ipilimumab: a case report.
     Melanoma Res. 2024;34:76-79.
     PubMed     Abstract available
     
     
     January 2024
130. DAVIDSON TM, Hieken TJ, Glasgow AE, Habermann EB, et al
     Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020.
     Melanoma Res. 2024 Jan 23. doi: 10.1097/CMR.0000000000000953.
     PubMed     Abstract available
     
     
     
131. KOSTAKI M, Plaka M, Befon A, Dessinioti C, et al
     Simultaneous melanomas in the setting of multiple primary melanomas.
     Melanoma Res. 2024 Jan 15. doi: 10.1097/CMR.0000000000000954.
     PubMed     Abstract available
     
     
     
132. PARISA S, Amirhossein I, Hamed YS, Javad F, et al
     The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity.
     Melanoma Res. 2024 Jan 15. doi: 10.1097/CMR.0000000000000931.
     PubMed     Abstract available
     
     
     
133. KO B, Tao K, Brennan L, Rakhade S, et al
     Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients.
     Melanoma Res. 2024 Jan 5. doi: 10.1097/CMR.0000000000000945.
     PubMed     Abstract available
     
     
     December 2023
134. LOUVEAU B, Reger De Moura C, Jouenne F, Sadoux A, et al
     Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models.
     Melanoma Res. 2023 Dec 22. doi: 10.1097/CMR.0000000000000950.
     PubMed     Abstract available
     
     
     
135. YEE J, Rosendahl C, Aoude LG
     The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective.
     Melanoma Res. 2023 Dec 22. doi: 10.1097/CMR.0000000000000951.
     PubMed     Abstract available
     
     
     
136. ROSHARDT PRIETO NM, Turko P, Zellweger C, Nguyen-Kim TDL, et al
     Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
     Melanoma Res. 2023 Dec 19. doi: 10.1097/CMR.0000000000000952.
     PubMed     Abstract available
     
     
     
137. YAN J, Wang H, Lu X, Li F, et al
     Development and validation of a nomogram for elderly patients with ulcerative melanoma.
     Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000940.
     PubMed     Abstract available
     
     
     
138. BAFALOUKOS D, Kouzis P, Gouveris P, Boukovinas I, et al
     Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter ch
     Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000949.
     PubMed     Abstract available
     
     
     
139. RICHTIG E, Nguyen VA, Koelblinger P, Wolf I, et al
     Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
     Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000948.
     PubMed     Abstract available
     
     
     
140. SWITZER B, Puzanov I, Gandhi S, Repasky EA, et al
     Targeting beta-adrenergic receptor pathways in melanoma: how stress modulates oncogenic immunity.
     Melanoma Res. 2023 Dec 4. doi: 10.1097/CMR.0000000000000943.
     PubMed     Abstract available
     
     
     
141. PARISI R, Shah H, Everdell E, Feustel P, et al
     First-time office visit for suspicious skin lesion evaluation as a predictor of high-risk melanoma.
     Melanoma Res. 2023;33:555-556.
     PubMed    
     
     
     
142. CARMONA-ROCHA E, Sullivan I, Yelamos O
     Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response.
     Melanoma Res. 2023;33:553-555.
     PubMed    
     
     
     
143. TAN SX, Chong S, Rowe C, Claeson M, et al
     pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma.
     Melanoma Res. 2023;33:506-513.
     PubMed     Abstract available
     
     
     
144. MEYER SN, Simmons E, Studer AC, Rauen KA, et al
     Melanocytic neoplasms in neurofibromatosis type 1: a systematic review.
     Melanoma Res. 2023;33:437-446.
     PubMed     Abstract available
     
     
     
145. VIGNESWARAN G, Malalasekera W, Smith V, Gibson T, et al
     Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic Uveal Melanoma.
     Melanoma Res. 2023 Dec 1. doi: 10.1097/CMR.0000000000000947.
     PubMed     Abstract available
     
     
     November 2023
146. STAHLIE EHA, Zijlker LP, Wouters MWJM, Schrage YM, et al
     Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma.
     Melanoma Res. 2023 Nov 28. doi: 10.1097/CMR.0000000000000946.
     PubMed     Abstract available
     
     
     
147. MEZOLAKI NE, Baltas E, Ocsai HL, Varga A, et al
     Tumour regression predicts better response to interferon therapy in melanoma patients: a retrospective single centre study.
     Melanoma Res. 2023 Nov 13. doi: 10.1097/CMR.0000000000000935.
     PubMed     Abstract available
     
     
     
148. KAHLER KC, Debus D, Schley G, Goppner D, et al
     Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS.
     Melanoma Res. 2023 Nov 13. doi: 10.1097/CMR.0000000000000908.
     PubMed     Abstract available
     
     
     
149. PAOLINO G, Carugno A, Rongioletti F, Ponzoni M, et al
     Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma.
     Melanoma Res. 2023 Nov 8. doi: 10.1097/CMR.0000000000000942.
     PubMed     Abstract available
     
     
     
150. CHEN W, Yang C, Chen B, Xi M, et al
     Management of metastatic bone disease of melanoma.
     Melanoma Res. 2023 Nov 8. doi: 10.1097/CMR.0000000000000937.
     PubMed     Abstract available
     
     
     
151. TAIBO A, Paradela S, Suanzes-Hernandez J, Balboa-Barreiro V, et al
     Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis.
     Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000920.
     PubMed     Abstract available
     
     
     
152. GAMBICHLER T, Iordanou M, Becker JC, Susok L, et al
     Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.
     Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000934.
     PubMed     Abstract available
     
     
     
153. KIM HE, Kim J, Park HK, Lee JB, et al
     Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas.
     Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000939.
     PubMed     Abstract available
     
     
     
154. BENESCH MGK, Skitzki JJ
     Impact of anesthesia choice in cutaneous melanoma surgery.
     Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000936.
     PubMed     Abstract available
     
     
     
155. KOHL LM, Sumpter TL
     Melanomas and mast cells: an ambiguous relationship.
     Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000932.
     PubMed     Abstract available
     
     
     October 2023
156. CAO Y, Afzal MZ, Gutmann EJ, Shirai K, et al
     Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors.
     Melanoma Res. 2023 Oct 13. doi: 10.1097/CMR.0000000000000925.
     PubMed     Abstract available
     
     
     
157. SADA I, Harada Y, Hiyama T, Mizukami M, et al
     Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma.
     Melanoma Res. 2023 Oct 2. doi: 10.1097/CMR.0000000000000933.
     PubMed     Abstract available
     
     
     
158. RUBATTO M, Borriello S, Sciamarrelli N, Pala V, et al
     Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies.
     Melanoma Res. 2023 Oct 2. doi: 10.1097/CMR.0000000000000926.
     PubMed     Abstract available
     
     
     
159. PHAM JP, Dwyer L, Phan K, Menzies AM, et al
     Efficacy of topical diphencyprone for melanoma in-transit metastases: a systematic review and meta-analysis.
     Melanoma Res. 2023;33:434-436.
     PubMed    
     
     
     
160. OZLUK AA, Karateke M, Sanli UA, Karaca B, et al
     Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis.
     Melanoma Res. 2023;33:417-421.
     PubMed     Abstract available
     
     
     September 2023
161. BOUDREAU MW, Tonogai EJ, Schane CP, Xi MX, et al
     The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma.
     Melanoma Res. 2023 Sep 22. doi: 10.1097/CMR.0000000000000927.
     PubMed     Abstract available
     
     
     
162. SEGURA S, Podlipnik S, Boada A, Marti RM, et al
     Melanoma-specific survival in worse in the elderly: a multicentric cohort study.
     Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000923.
     PubMed     Abstract available
     
     
     
163. LIN Z, Shen H, Liu X, Ma W, et al
     Recent advances of artificial intelligence in melanoma clinical practice.
     Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000922.
     PubMed     Abstract available
     
     
     
164. UEMATSU M, Nakajima H, Hosono A, Kiyohara H, et al
     Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series.
     Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000924.
     PubMed     Abstract available
     
     
     August 2023
165. LUO S, Xie C, Lin N, Lin D, et al
     Cost-effectiveness analysis of an orphan drug-tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing.
     Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000919.
     PubMed     Abstract available
     
     
     
166. MATTEI J, Trindade EN, Chedid MF
     Mucosal melanoma: from molecular landscape to current treatment strategies.
     Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000916.
     PubMed     Abstract available
     
     
     
167. MILEY DR, Andrews-Pfannkoch CM, Pulido JS, Erickson SA, et al
     Direct early growth response-1 knockdown decreases melanoma viability independent of mitogen-activated extracellular signal-related kinase inhibition.
     Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000921.
     PubMed     Abstract available
     
     
     
168. LIU M, Lan Y, Zhang H, Zhang X, et al
     Telomere length is associated with increased risk of cutaneous melanoma: a Mendelian randomization study.
     Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000917.
     PubMed     Abstract available
     
     
     
169. GJORUP CA, Pires da Silva I, Martin L, Stretch JR, et al
     Definitive treatment with PD-1 blockade and radiation therapy of unresected primary desmoplastic melanoma of the nose.
     Melanoma Res. 2023 Aug 3. doi: 10.1097/CMR.0000000000000905.
     PubMed     Abstract available
     
     
     
170. AUGUSTYN K, Joseph J, Patel AB, Razmandi A, et al
     Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.
     Melanoma Res. 2023 Aug 3. doi: 10.1097/CMR.0000000000000891.
     PubMed     Abstract available
     
     
     July 2023
171. GLINKINA KA, Teunisse AFAS, Gelmi MC, de Vries J, et al
     Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
     Melanoma Res. 2023 Jul 18. doi: 10.1097/CMR.0000000000000911.
     PubMed     Abstract available
     
     
     
172. FELICI C, Passarelli A, Cafforio P, Racanelli V, et al
     Lenalidomide arrests cell cycle and modulates PD1-dependent downstream mTOR intracellular signals in melanoma cells.
     Melanoma Res. 2023 Jul 12. doi: 10.1097/CMR.0000000000000913.
     PubMed     Abstract available
     
     
     
173. PELIZZARI G, Bertoli E, Buriolla S, Vitale MG, et al
     Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase.
     Melanoma Res. 2023 Jul 3. doi: 10.1097/CMR.0000000000000907.
     PubMed     Abstract available
     
     
     June 2023
174. GIRONI LC, Esposto E, Zottarelli F, Giorgione R, et al
     Temporal correlation between the first melanoma and the first noncutaneous tumor in CKDN2A genotyped patients.
     Melanoma Res. 2023 Jun 21. doi: 10.1097/CMR.0000000000000906.
     PubMed     Abstract available
     
     
     
175. HE K, Hong DS, Ke D, Kebriaei P, et al
     Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report.
     Melanoma Res. 2023 Jun 16. doi: 10.1097/CMR.0000000000000869.
     PubMed     Abstract available
     
     
     
176. ASSEFA W, Muluye S, Assefa A, Alemu Y, et al
     A glimpse at locally advanced melanomas in the settings of poverty: pathologists viewpoint.
     Melanoma Res. 2023 Jun 13. doi: 10.1097/CMR.0000000000000909.
     PubMed     Abstract available
     
     
     
177. KISISTOK J, Christensen DS, Rasmussen MH, Duval L, et al
     Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel.
     Melanoma Res. 2023 Jun 12. doi: 10.1097/CMR.0000000000000903.
     PubMed     Abstract available
     
     
     
178. GARCIA-PEREZ O, Melgar-Vilaplana L, Sifaoui I, Garcia-Bello MA, et al
     Expression of angiogenic and lymphangiogenic genes in primary cutaneous melanoma: relationship with angiolymphatic invasion and disease-free survival.
     Melanoma Res. 2023 Jun 12. doi: 10.1097/CMR.0000000000000904.
     PubMed     Abstract available
     
     
     
179. AMARA SV, Grbic N, Melson G, Brem CE, et al
     Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection.
     Melanoma Res. 2023 Jun 5. doi: 10.1097/CMR.0000000000000902.
     PubMed     Abstract available
     
     
     
180. CHERSI F, Conforti C, Zalaudek I, Bazzacco G, et al
     Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient.
     Melanoma Res. 2023;33:262-263.
     PubMed    
     
     
     May 2023
181. AGNILA DRL, Huda TI, Eakins RA, Patel DN, et al
     Chemical features of melanoma tumor resident TRG CDR3s associated with better survival probabilities.
     Melanoma Res. 2023 May 23. doi: 10.1097/CMR.0000000000000899.
     PubMed     Abstract available
     
     
     
182. SHELLENBERGER RA, Gowda S, Kurn H, Albright J, et al
     Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis.
     Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000897.
     PubMed     Abstract available
     
     
     
183. PHAM JP, On L, Ardolino L, Hurwitz J, et al
     Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis.
     Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000900.
     PubMed     Abstract available
     
     
     
184. YOO H, Park S, Kim SW
     Nodular type predominance of head and neck cutaneous malignant melanoma in Asian populations leads to poor outcome and low survival.
     Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000901.
     PubMed     Abstract available
     
     
     
185. MATTAVELLI I, Patuzzo R, Galeone C, Pelucchi C, et al
     Potential risk factors, clinicopathological features and determinants of survival for multiple primary melanoma patients compared to single primary melanoma: a large single-center Italian study.
     Melanoma Res. 2023 May 8. doi: 10.1097/CMR.0000000000000898.
     PubMed     Abstract available
     
     
     
186. OGATA D, Nishio S, Hatta N, Kaji T, et al
     Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan.
     Melanoma Res. 2023 May 8. doi: 10.1097/CMR.0000000000000894.
     PubMed     Abstract available
     
     
     April 2023
187. DIRVEN I, Vander Mijnsbrugge AS, Mignon S, Tijtgat J, et al
     Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia: a case series and literature review.
     Melanoma Res. 2023 Apr 28. doi: 10.1097/CMR.0000000000000895.
     PubMed     Abstract available
     
     
     
188. WONG CK, Dite GS, Spaeth E, Murphy NM, et al
     Melanoma risk prediction based on a polygenic risk score and clinical risk factors.
     Melanoma Res. 2023 Apr 24. doi: 10.1097/CMR.0000000000000896.
     PubMed     Abstract available
     
     
     
189. MOHAMMADI A, Najafi S, Amini M, Baradaran B, et al
     B7H6 silencing increases chemosensitivity to dacarbazine and suppresses cell survival and migration in cutaneous melanoma.
     Melanoma Res. 2023 Apr 12. doi: 10.1097/CMR.0000000000000890.
     PubMed     Abstract available
     
     
     
190. STATHAKI MI, Kapsoritakis N, Michelakis D, Anagnostopoulou E, et al
     The impact of sentinel lymph node mapping with hybrid single photon emission computed tomography/computed tomography in patients with melanoma. Comparison to planar radioisotopic lymphoscintigraphy.
     Melanoma Res. 2023 Apr 12. doi: 10.1097/CMR.0000000000000893.
     PubMed     Abstract available
     
     
     
191. BRUNSGAARD EK, Bowles TL, Asare EA, Grossmann K, et al
     Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma.
     Melanoma Res. 2023 Apr 5. doi: 10.1097/CMR.0000000000000892.
     PubMed     Abstract available
     
     
     
192. CYBULSKA-STOPA B, Piejko K, Ostaszewski K, Dziura R, et al
     Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment.
     Melanoma Res. 2023 Apr 3. doi: 10.1097/CMR.0000000000000885.
     PubMed     Abstract available
     
     
     March 2023
193. MANZANO JL, Martin-Liberal J, Fernandez-Morales LA, Benitez G, et al
     Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study.
     Melanoma Res. 2023 Mar 28. doi: 10.1097/CMR.0000000000000888.
     PubMed     Abstract available
     
     
     
194. VUILLAMY C, Arnault JP, Fumery M, Mortier L, et al
     Clostridium difficile infection and immune checkpoint inhibitor-induced colitis in melanoma: 18 cases and a review of the literature.
     Melanoma Res. 2023 Mar 27. doi: 10.1097/CMR.0000000000000878.
     PubMed     Abstract available
     
     
     
195. YANG H, Zhou J, Li D, Zhou S, et al
     The inhibitory role of microRNA-141-3p in human cutaneous melanoma growth and metastasis through the fibroblast growth factor 13-mediated mitogen-activated protein kinase axis.
     Melanoma Res. 2023 Mar 21. doi: 10.1097/CMR.0000000000000873.
     PubMed     Abstract available
     
     
     
196. BOILEAU M, Templier C, Massip E, Dehoux C, et al
     Description of supportive care and feasibility of physical exercise program to improve quality of life in advanced melanoma patients.
     Melanoma Res. 2023 Mar 17. doi: 10.1097/CMR.0000000000000889.
     PubMed     Abstract available
     
     
     
197. PIGNE T, Levy M, Ducharme O, Dutriaux C, et al
     Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma.
     Melanoma Res. 2023 Mar 15. doi: 10.1097/CMR.0000000000000884.
     PubMed     Abstract available
     
     
     
198. BOILEAU M, Descarpentries C, Delzenne G, Trentesaux V, et al
     Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene.
     Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000882.
     PubMed     Abstract available
     
     
     
199. JASSO-SOSA VY, Lino-Silva LS, Escobar-Jimenez MG, Galvan-Bustillos JR, et al
     Prognosis of polypoid melanoma: a comparative study with non-polypoid melanomas.
     Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000886.
     PubMed     Abstract available
     
     
     
200. BERBERICH C, Mustafa M, Zhuwu Y, Gaa J, et al
     The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [18F]-fluorodeoxyglucose PET/computed tomography.
     Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000883.
     PubMed     Abstract available
     
     
     February 2023
201. KOMULAINEN J, Siiskonen H, Haimakainen S, Kanasuo E, et al
     Patients with a history of atopy have fewer cutaneous melanomas than those without atopy: a cross-sectional study in 496 patients at risk of skin cancers.
     Melanoma Res. 2023 Feb 28:e000887. doi: 10.1097/CMR.0000000000000887.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum